Salix Pharmaceuticals, Ltd. (SLXP) Announces Initiation of Target 3: A Phase 3 Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550MG TID in Subjects with Irritable Bowel Syndrome with Diarrhea
2/21/2012 10:25:32 AM
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the initiation of TARGET 3 - a Phase 3 study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days in subjects with IBS-D who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. The study will screen subjects with IBS-D, treat them with rifaximin and follow those that respond to this initial course of therapy until their symptoms recur, at which time they will undergo double-blind randomization to either another course of rifaximin 550 mg TID for 14 days or matching placebo. Approximately 800 subjects (adults with IBS-D) will be randomized (400 per treatment group) into the double blind retreatment phase of the study.